爱尔眼科(300015) - 2017 Q4 - 年度业绩预告

Financial Performance - The company's net profit for the reporting period is expected to be between 72,470.74 million RMB and 75,258.07 million RMB, representing a year-on-year growth of 30%-35%[3] - The previous year's net profit was 55,746.72 million RMB, indicating a significant increase in profitability[3] - The growth in net profit is attributed to the expansion of the company's operational scale, with increased outpatient and surgical volumes across its hospitals[5] - Non-recurring losses are estimated to impact net profit by approximately -35 million RMB[7] Strategic Implementation - The company's international strategy has been successfully implemented, contributing to the growth in market share and operational efficiency[5] - The company's brand influence has been steadily increasing, leading to improved business performance and revenue growth[5] Financial Reporting - The financial data presented in the earnings forecast has not been audited by registered accountants[4] - The detailed financial data will be disclosed in the 2017 annual report[7] Investor Guidance - The company emphasizes the importance of rational investment and risk awareness for investors[7] Reporting Period - The earnings forecast period covers January 1, 2017, to December 31, 2017[3]